Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Case Studies_ Stahl's Essential - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
2 Мб
Скачать
☆

Case debrief

This patient does not have a clear categorical diagnosis outside AUD

In the DSM-5, there continues to be the categorical use of the intoxication and withdrawal diagnoses, but the use of “abuse” and “dependence” has been removed

  • – Instead, the term for AUD is employed to describe patients who overuse this substance and develop consequences in psychosocial functioning

  • – If two or more symptoms of abuse/dependence are noted, then the patient would be classified as suffering from mild AUD

    • Four or more symptoms is moderate AUD

    • Six or more symptoms is severe AUD

The depression, anxiety, and insomnia are problematic and likely fuel some of his excessive alcohol use. These are viewed as adjustment disorders and that he has limited coping skills to manage new stressors at times

He tapered off his sedative and hypnotic after being placed on gabapentin (Neurontin) 900 mg/d in divided doses for one week

He continued his sertraline (Zoloft) 50 mg/d

He returned, stating that he was sleeping well and that his mood and anxiety were gradually and constantly improving

He remained alcohol sober

He had mild headaches as the only side effect

He was returning to graduate school shortly, wanted to continue both medications, and had set up an appointment with a psychodynamically oriented psychotherapist there

Take-home points

Some patients do not have bona fide DSM-5 categorical disorders. In this case, the patient may have had AUD, other specified depressive disorder (recurrent brief depression), other specified anxiety disorder, adjustment disorder, and insomnia disorder

They do have impairing symptoms, target symptoms, that can be quantified and treated psychopharmacologically

In these cases, instead of choosing several medications to treat each individual DSM-5 minor entity or each clinical subsyndromal symptom cluster, attempt to choose a single medicine that may be able address multiple phenomenological symptom clusters

Performance in practice: confessions of a psychopharmacologist

What could have been done better here?

  • – Would a monotherapy of a non-SSRI be helpful?

    • Perhaps, in that he had two low therapeutic-dose trials of SSRIs. He may also have been better served by using an SNRI, SARI, or NaSSA monotherapy

    • Using a more sedating antidepressant with antihistamine properties could possibly treat his dysphoria, worry, and insomnia

  • – Could his BZ have been more adequately dosed?

    • His sedative–anxiolytic was dosed low and increasing it may have been able to better treat his anxiety and insomnia

    • This might be considered risky given his excessive AUD patterns

Possible action items for improvement in practice

  • – Research the risks of sedative dose escalation and abuse in non-addictive patients and those with previous or current addictive histories

  • – Research non-addictive treatment options for treating anxious and insomnic patients who suffer from comorbid addictions

  • – Research strategies for treating resistant anxiety and resistant insomnia

Tips and pearls

Non-addictive strategies for treating target symptoms of anxiety include

  • – Antihistamines

    • Hydroxyzine (Vistaril/Atarax)

  • – Serotonergic agents

    • Buspirone (BuSpar)

    • SSRI

    • SNRI

    • SARI

    • SPARI

  • – Antiepileptics

    • Gabapentin (Neurontin)

    • Pregabalin (Lyrica)

    • Topiramate (Topamax)

  • – Antipsychotics

    • Typical

      • Chlorpromazine (Thorazine)

      • Perphenazine (Trilafon)

    • Atypical

      • Sedating atypical antipsychotics

        • Quetiapine (Seroquel)

        • Olanzapine (Zyprexa)

        • Asenapine (Saphris)

Non-addictive strategies for treating target symptoms of insomnia include

  • – Antihistamines

    • Doxepin (Silenor)

    • Diphenhydramine (Benadryl)

    • Doxylamine (Unisom)

  • – Sedating antidepressants

    • TCA (imipramine, amitriptyline, clomipramine, doxepin)

    • NaSSA

  • – Antiepileptics

    • Gabapentin (Neurontin)

    • Pregabalin (Lyrica)

    • Tiagabine (Gabitril)

  • – Melatonin agonists

    • Ramelteon (Rozerem), tasimelteon (Hetlioz)

  • – Antipsychotics

    • Typicals

      • Sedating typical antipsychotics

        • Chlorpromazine (Thorazine)

        • Thioridazine (Mellaril)

    • Atypicals

      • Sedating atypical antipsychotics

        • Quetiapine (Seroquel)

        • Olanzapine (Zyprexa)

        • Asenapine (Saphris)

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]